Bridging Laboratory and Large Scale Production: Preparation and in Vitro-Evaluation of Photosensitizer-Loaded Nanocarrier Devices for Targeted Drug Delivery

Pharmaceutical Research

Volumn 32, Issue 5, 2015, Pages 1714-1726

  Beyer, Susanne ^a   Xie, Li ^a   Gräfe, Susanna ^b   Vogel, Vitali ^a   Dietrich, Kerstin ^a   Wiehe, Arno ^b   Albrecht, Volker ^b   Mäntele, Werner ^a   Wacker, Matthias G ^c  

^a GOETHE UNIVERSITY   (Germany)

^b Biolitec Research GmbH   (Germany)

^c FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

Design of Experiments; Drug targeting; Eudragit RS 100; Nanoparticles; Photodynamic therapy

Indexed keywords

DELAYED RELEASE FORMULATION; GLYCOFUROL; MACROGOL DERIVATIVE; MESOPORPHYRIN; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; NANOPARTICLE; PHOTOSENSITIZING AGENT; POLYMETHACRYLIC ACID DERIVATIVE; TEMOPORFIN;

CELL LINE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; HUMAN;

CELL LINE; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; MESOPORPHYRINS; NANOPARTICLES; PHOTOSENSITIZING AGENTS; POLYETHYLENE GLYCOLS; POLYMETHACRYLIC ACIDS;

EID: 84934768203     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1569-y     Document Type: Article

References (39)

1. Barenholz Y. Doxil® - the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-34.
2. Lautenschlager C, Schmidt C, Lehr CM, Fischer D, Stallmach A. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur J Pharm Biopharm. 2013;85(3 Pt A):578-86.
3. Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001;18(6):788-93.
4. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161(2):175-87.
5. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55(1):1-4.
6. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm. 2003;257(1-2):169-80.
7. Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res. 1998;150(5 Suppl):146-56.
8. Karnik R, Gu F, Basto P, Cannizzaro C, Dean L, Kyei-Manu W, et al. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano letters. 2008;8(9):2906-12.
9. Zhao C-X, He L, Qiao SZ, Middelberg AP. Nanoparticle synthesis in microreactors. Chemical Engineering Science. 2011;66(7):1463-79.
10. Santos RJ, Sultan MA. State of the art of mini/μ Jet reactors. Chemical Engineering & Technology. 2013;36(6):937-49.
11. Petschacher C, Eitzlmayr A, Besenhard M, Wagner J, Barthelmes J, Bernkop-Schnürch A, et al. Thinking continuously: a microreactor for the production and scale-up of biodegradable, self-assembled nanoparticles. Polymer Chemistry. 2013;4(7):2342-52.
12. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55(1):145-57.
13. Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol. 2008;26(11):612-21.
14. Dougherty TJ. Photodynamic therapy (PDT) of malignant tumors. Crit Rev Oncol Hematol. 1984;2(2):83-116.
15. Bodmeier R, Chen H, Tyle P, Jarosz P. Spontaneous formation of drug-containing acrylic nanoparticles. J Microencapsul. 1991;8(2):161-70.
16. Viehof A, Javot L, Beduneau A, Pellequer Y, Lamprecht A. Oral insulin delivery in rats by nanoparticles prepared with non-toxic solvents. Int J Pharm. 2013;443(1-2):169-74.
17. Wacker M, Chen K, Preuss A, Possemeyer K, Roeder B, Langer K. Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties Int J Pharm. 2010;393(1-2):253-62.
18. Vogel V, Langer K, Balthasar S, Schuck P, Mächtle W, Haase W, et al. Characterization of serum albumin nanoparticles by sedimentation velocity analysis and electron microscopy. Analytical Ultracentrifugation VI: Springer; 2002. p. 31-36.
19. Bootz A, Vogel V, Schubert D, Kreuter J. Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm. 2004;57(2):369-75.
20. Schuck P, Rossmanith P. Determination of the sedimentation coefficient distribution by least-squares boundary modeling. Biopolymers. 2000;54(5):328-41.
21. Porsch B, Hillang I, Karlsson A, Sundelof LO. Ion-exclusion controlled size-exclusion chromatography of methacrylic acid-methyl methacrylate copolymers. J Chromatogr A. 2000;872(1-2):91-9.
22. Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Development of different temoporfin-loaded invasomes-novel nanocarriers of temoporfin: characterization, stability and in vitro skin penetration studies. Colloids Surf B Biointerfaces. 2009;70(2):198-206.
23. Wacker M, Zensi A, Kufleitner J, Ruff A, Schutz J, Stockburger T, et al. A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation. Int J Pharm. 2011;414(1-2):225-32.
24. Wacker M. Nanocarriers for intravenous injection-the long hard road to the market. Int J Pharm. 2013;457(1):50-62.
25. Wacker MG. Nanotherapeutics-product development along the "nanomaterial" discussion. J Pharm Sci. 2014;103(3):777-84.
26. Moulari B, Pertuit D, Pellequer Y, Lamprecht A. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials. 2008;29(34):4554-60.
27. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135-46.
28. Tscharnuter W. Photon correlation spectroscopy in particle sizing. In: Meyers RA, editor. Encyclopedia of analytical chemistry. Chinchester: Wiley; 2000. p. 5469-85.
29. Ali ME, Lamprecht A. Polyethylene glycol as an alternative polymer solvent for nanoparticle preparation. Int J Pharm. 2013;456(1):135-42.
30. Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008;105(33):11613-8.
31. Wang J, Byrne JD, Napier ME, DeSimone JM. More effective nanomedicines through particle design. Small. 2011;7(14):1919-31.
32. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19.33.
33. Günther A, Jhunjhunwala M, Thalmann M, Schmidt MA, Jensen KF. Micromixing of miscible liquids in segmented gas-liquid flow. Langmuir. 2005;21(4):1547-55.
34. Jensen KF. Microreaction engineering - is small better? Chemical Engineering Science. 2001;56(2):293-303.
35. Li W, Greener J, Voicu D, Kumacheva E. Multiple modular microfluidic (M 3) reactors for the synthesis of polymer particles. Lab on a Chip. 2009;9(18):2715-21.
36. Türeli AE, Penth B, Langguth P, Baumstümmler B. Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren. German Patent Application DE102009008478A1; 2011.
37. Wu H, White M, Khan MA. Quality-by-Design (QbD): An integrated process analytical technology (PAT) approach for a dynamic pharmaceutical co-precipitation process characterization and process design space development. Int J Pharm. 2011;405(1-2):63-78.
38. Yu LX, Lionberger RA, Raw AS, D'Costa R, Wu H, Hussain AS. Applications of process analytical technology to crystallization processes. Adv Drug Deliv Rev. 2004;56(3):349-69.
39. Wu H, Khan MA. Quality-by-design: an integrated process analytical technology approach to determine the nucleation and growth mechanisms during a dynamic pharmaceutical coprecipitation process. J Pharm Sci. 2011;100(5):1969-86.